ABSTRACT
OBJECTIVE: To study the effect of nicorandil on the elasticity of the great vessels, cardiac functional parameters and quality of life in patients with coronary heart disease (CHD). MATERIAL AND METHODS: In a double-blind, randomized, placebo-controlled trial of nicorandil was attended by 154 patients with stable angina III functional class (FC), divided into 2 comparable age and sex group. Study duration was 12 months. RESULTS: In the group treated with nicorandil compared with placebo, the number of angina attacks and nitrate intake of short-significantly reduced, improved elastic properties of large arteries, improved quality of life. In a cohort of patients with CHD and left ventricular ejection fraction less than 45% nikorandil addition to standard therapy has improved the systolic function of the heart and reduce left ventricular remodeling. CONCLUSION: The use of nicorandil in addition to standard therapy can not only improve the quality of life in patients with coronary artery disease, but also a positive impact on the state of elasticity of blood vessels and morpho-functional parameters of the heart.
Subject(s)
Angina, Stable , Nicorandil/therapeutic use , Vascular Stiffness/drug effects , Vasodilator Agents/therapeutic use , Aged , Aged, 80 and over , Angina, Stable/drug therapy , Angina, Stable/physiopathology , Angina, Stable/psychology , Double-Blind Method , Female , Humans , Male , Middle Aged , Prognosis , Quality of Life , Random AllocationABSTRACT
The diurnal profile peculiarities in normotensive elderly persons have been shown. The variability ranges of systolic arterial blood pressure are discussed.
Subject(s)
Blood Pressure/physiology , Circadian Rhythm/physiology , Age Factors , Aged , Aged, 80 and over , Female , Humans , MaleABSTRACT
AIM: To examine effectiveness and safety of quadropril. MATERIAL AND METHODS: Changes in blood pressure (BP), heart rate (HR), levels of glucose, potassium and creatinine, creatinine clearance were studied in 120 patients (48 males and 72 females, mean age 60.6 +/- 0.7 years) with mild to moderate arterial hypertension (AH) with average duration 13.8 +/- 0.7 years. The patients were divided into 3 groups: with AH (n = 40), AH + noninsulindependent diabetes mellitus (DM) (n = 43), AH and nephropathy (n = 37). 8-week treatment was performed with a standard dose of 6 mg/day (1 tablet of quadropril). Control examinations were made 2, 4 and 8 weeks after the treatment. RESULTS: After 8 weeks of treatment a decrease in systolic blood pressure in AH group was 24.0 +/- 3.0 mm Hg and in diastolic blood pressure 16.3 +/- 1.3 mm Hg (P < 0.001). In the group with DM this decrease was 22.4 +/- 2.8 mm Hg and 15.7 +/- 1.4 mm Hg (p < 0.001), respectively. In the group with nephropathy this decrease was 26.4 +/- 2.4 and 16.5 +/- 1.3 mm Hg (p < 0.001), respectively. Heart rate changed significantly only in diabetics: from 75.1 +/- 1.7 to 72.9 +/- 1.3 beats/min. Biochemical parameters in the hypertensive and diabetic patients did not change significantly. In the nephropathy group there was a significant decrease in creatinine and increase in creatinine clearance. Their level of glucose and potassium changed insignificantly. CONCLUSION: The treatment with quadropril results in a significant decrease in blood pressure, does not influence parameters of carbohydrate metabolism, improves nitrogen eliminating function of the kidneys.
Subject(s)
Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/complications , Enalapril/administration & dosage , Hypertension/drug therapy , Administration, Oral , Adult , Aged , Blood Glucose/metabolism , Blood Pressure/drug effects , Creatinine/blood , Creatinine/urine , Delayed-Action Preparations , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/physiopathology , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/physiopathology , Enalapril/analogs & derivatives , Female , Heart Rate/drug effects , Humans , Hypertension/complications , Hypertension/metabolism , Hypertension/physiopathology , Male , Middle Aged , Safety , Treatment OutcomeABSTRACT
The active forms of oxygen (AFA) participate in modulation of mediation processes in patients with systemic lupus erythematosus. A direct correlation of AFA with serotonin and kallikrein was noted, a reverse one with the inhibitory systems. Reactivity of AFA proved to be most marked in patients with lupus nephritis. The role of polymorphonuclear leukocytes in the activation of vasculo-thrombocytic hemostasis is discussed.
